从传统他汀及其联合治疗看调脂治疗的临床获益

New perspectives on cardiovascular benefits of conventional statins and their combination therapy for lipid regulation

动脉粥样硬化性心血管疾病(ASCVD)是全球范围内主要的疾病负担,亦是患者死亡的主要原因。既往大量关于他汀类药物调脂治疗的临床试验证实,他汀类药物可有效降低ASCVD患者低密度脂蛋白胆固醇(LDL-C)水平、全因死亡率和心血管病死亡率,无ASCVD的患者亦可获益。然而,目前无论是ASCVD高危患者还是无ASCVD的人群,并未广泛应用降脂治疗。因此,本文阐述了他汀类及其联合用药所带来的临床获益,旨在增大受益人群,改善预后。

Atherosclerotic cardiovascular diseases(ASCVD) are the major causes of morbidity and mortality worldwide.Previous randomized controlled trials confirm that statin therapy can effectively reduce the level of low density lipoproteincholesterol(LDL-C), all-cause and cardiovascular disease mortality in patients with and without ASCVD. However, there isno widespread use of lipid-lowering therapy to achieve the benefit in high risk patients with ASCVD and patients withoutASCVD. Therefore, it is necessary to further elaborate the clinical benefits of statins and their combined use for lipidregulating therapy and increasing the beneficiaries.